The first-ever CRISPR-based gene-editing therapy has been approved for marketing ... before reinfusing them to treat the diseases. The aim of the treatment is to modify the cells to make foetal ...

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR is hard to do profitably.

A cutting-edge gene therapy has been approved for NHS use for some patients with severe sickle cell disease. Casgevy, also ...

People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...

Editas and CRISPR are probably most closely linked as they both pursued Sickle Cell Disease ... and become the first CRISPR based gene editing treatment to receive FDA approval.

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...

Exagamglogene autotemcel (exa-cel) gene therapy offers a potential cure for severe sickle cell disease, now available on NHS.

Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the ...

Casgevy, also known as exa-cel, was the first treatment to be licensed using gene-editing tool Crispr ... has been approved for use for certain patients with severe sickle cell disease.